Difenossilato [Dcit]

Difenossilato [Dcit] Brand names, Difenossilato [Dcit] Analogs

Difenossilato [Dcit] Brand Names Mixture

Lomotil (Atropine Sulfate + Diphenoxylate Hcl)

Difenossilato [Dcit] Chemical_Formula

C₃₀H₃₂N₂O₂

Difenossilato [Dcit] RX_link

http://www.rxlist.com/cgi/generic3/diphenoxylate.htm

Difenossilato [Dcit] fda sheet

Difenossilato [Dcit] msds (material safety sheet)

Difenossilato_[Dcit] MSDS

Difenossilato [Dcit] Synthesis Reference

Janssen, U.S. pat. 2,898,340 (1959)

Difenossilato [Dcit] Molecular Weight

452.587 g/mol

Difenossilato [Dcit] Melting Point

221 ^oC

Difenossilato [Dcit] H₂O Solubility

0.8 mg/ml

Difenossilato [Dcit] State

Solid

Difenossilato [Dcit] LogP

7.385

Difenossilato [Dcit] Dosage Forms

Oral solution; Tablet

Difenossilato [Dcit] Indication

For as adjunctive therapy in the management of diarrhea

Difenossilato [Dcit] Pharmacology

Diphenoxylate, an antidiarrheal, is effective as adjunctive therapy in the management of diarrhea. Diphenoxylate is rapidly and extensively metabolized in man by ester hydrolysis to diphenoxylic acid (difenoxine), which is biologically active and the major metabolite in the blood.

Difenossilato [Dcit] Absorption

90%

Difenossilato [Dcit] side effects and Toxicity

Coma, dry skin and mucous membranes, enlarged pupils of the eyes, extremely high body temperature, flushing, involuntary eyeball movement, lower than normal muscle tone, pinpoint pupils, rapid heartbeat, restlessness, sluggishness, suppressed breathing

Difenossilato [Dcit] Patient Information

INFORM THE PATIENT (PARENT OR GUARDIAN) NOT TO EXCEED THE RECOMMENDED DOSAGE AND TO KEEP DIPHEN-OXYLATE HCL AND ATROPINE SULFATE OUT OF THE REACH OF CHILDREN AND IN A CHILD-RESISTANT CONTAINER, INFORM THE PATIENT OF THE CONSEQUENCES OF OVERDOSAGE, INCLUDING SEVERE RESPIRATORY DEPRESSION AND COMA, POSSIBLY LEADING TO PERMANENT BRAIN DAMAGE OR DEATH.

Diphenoxylate HCl and atropine sulfate may produce drowsiness or dizziness. The patient should be cautioned regarding activities requiring mental alertness, such as driving or operati ng dangerous machinery. Potentiation of the action of alcohol, barbiturates and tranquilizers with concomitant use of diphenoxylate HCl and atropine sulfate should be explained to the patient. The physician should also provide the patient with other information in this labeling, as appropriate.

Difenossilato [Dcit] Organisms Affected

Humans and other mammals